Symptoms and patient-reported well-being: Do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma

Journal of Clinical Oncology

Volumn 25, Issue 36, 2007, Pages 5770-5776

  Bottomley, Andrew ^a   Coens, Corneel ^a   Efficace, Fabio ^a   Gaafar, Rabab ^a   Manegold, Christian ^a   Burgers, Sjaak ^a   Vincent, Mark ^a   Legrand, Catherine ^a   van Meerbeeck, Jan P ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; RALTITREXED;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PAIN; PHASE 3 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; WORLD HEALTH ORGANIZATION;

ANTINEOPLASTIC AGENTS; CISPLATIN; FEMALE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUINAZOLINES; SELF ASSESSMENT (PSYCHOLOGY); THIOPHENES;

EID: 37649023682     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.5294     Document Type: Article

References (31)

1. Steele JP, Klabatsa A: Chemotherapy options and new advances in malignant pleural mesothelioma. Ann Oncol 16:345-351, 2005
2. Fennell DA, Parmar A, Shamash J, et al: Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J Clin Oncol 23:184-189, 2005
3. Curran D, Sahmoud T, Therasse P, et al: Prognostic factors in patients with pleural mesothelioma: The EORTC experience. J Clin Oncol 16:145-152, 1998
4. Peto J, Decarli A, La Vecchia C, et al: The European mesothelioma epidemic. Br J Cancer 79:666-672, 1999
5. Parker C, Neville E: Lung cancer: Management of malignant mesothelioma. Thorax 58:809-813, 2003
6. Muers MF, Rudd RM, O'Brien ME, et al: BTS randomized feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112. Thorax 59:144-148, 2004
7. Legrand C, Gaafar R, Manegold C, et al: Prognostic factor analysis of EORTC 08983: A randomized phase III study of cisplatin with or without raltitrexed in patients (pts) with malignant pleural mesothelioma (MPM). Lung Cancer 49:224, 2005 (abstr P-410)
8. Fang FM, Liu YT, Tang Y, et al: Quality of life as a survival predictor for patients with advanced head and neck carcinoma treated with radiotherapy. Cancer 100:425-432, 2004
9. Blazeby JM, Brookes ST, Alderson D: The prognostic value of quality of life scores during treatment for oesophageal cancer. Gut 49:227-230, 2001
10. Kramer JA, Curran D, Piccart M, et al: Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. Eur J Cancer 36:1498-1506, 2000
11. Efficace F, Therasse P, Piccart M, et al: Health-related quality of life parameters as prognostic factors in a non-metastatic breast cancer population: An international multicenter study. J Clin Oncol 22:3381-3388, 2004
12. Coates A, Forbes J, Simes RJ: Prognostic value of performance status and quality-of-life scores during chemotherapy for advanced breast cancer: The Australian New Zealand Breast Cancer Trials Group. J Clin Oncol 11:2050, 1993
13. Kaasa S, Mastekaasa A, Lund E: Prognostic factors for patients with inoperable non-small cell lung cancer, limited disease: The importance of patients' subjective experience of disease and psychosocial well-being. Radiother Oncol 15:235-242, 1989
14. Herndon JE, Fleishman S, Kornblith AB, et al: Is quality of life predictive of the survival of patients with advanced non-small cell lung carcinoma? Cancer 85:333-340, 1999
15. Naughton MJ, Herndon JE II, Shumaker SA, et al: The health-related quality of life and survival of small-cell lung cancer patients: Results of a companion study to CALGB 9033. Qual Life Res 11:235-248, 2002
16. Eton DT, Fairclough DL, Cella D, et al: Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: Results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol 21:1536-1543, 2003
17. Nowak AK, Stockler MR, Byrne MJ: Assessing quality of life during chemotherapy for pleural mesothelioma: Feasibility, validity, and results of using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module. J Clin Oncol 22:3172-3180, 2004
18. van Meerbeeck, Gaafar R, Manegold C, et al: Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23:6881-6889, 2005
19. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
20. Bergman B, Aaronson NK, Ahmedzai S, et al: The EORTC QLQ-LC13: A modular supplement to the EORTC Core Quality of Life Questionnaire (QLQC30) for use in lung cancer clinical trials - EORTC Study Group on Quality of Life. Eur J Cancer 30A:635-642, 1994
21. Fayers P, Aaronson N, Bjordal K, et al: EORTC QLQ-C30 Scoring Manual (ed 3). Brussels, Belgium, EORTC Publications, 2001
22. Harrell FE, Lee KL, Mark DB: Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361-387, 1996
23. Sauerbrei W, Schumacher M: A bootstrap resampling procedure for model building: Application to the Cox regression model. Stat Med 11:2093-2109, 1992
24. Van Steen, Curran D, Kramer J, et al: Multicollinearity in prognostic factor analyses using the EORTC QLQ-C30: Identification and impact on model selection. Stat Med 21:3865-3884, 2002
25. Bottomley A, Smit E, Efficace F, et al: Non-small cell lung cancer and health-related quality of life (HRQOL): Is baseline HRQOL of prognostic value for survival? Qual Life Res 14:2050, 2005 (abstr)
26. Roychowdhury DF, Hayden A, Liepa AM: Health-related quality-of-life parameters as independent prognostic factors in advanced or metastatic bladder cancer. J Clin Oncol 21:673-678, 2003
27. Coates AS, Hurny C, Peterson HF, et al: Quality-of-life scores predict outcome in metastatic but not early breast cancer: International Breast Cancer Study Group. J Clin Oncol 18:3768-3774, 2000
28. Efficace F, Biganzoli L, Piccart M, et al: Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. Eur J Cancer 40:1021-1030, 2004
29. Brown J, Thorpe H, Napp V, et al: Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer. J Clin Oncol 23:7417-7427, 2005
30. Collette L, Van Andel G, Bottomley A, et al: Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group. J Clin Oncol 22:3877-3885, 2004
31. Fayers P, Weeden S, Curran D: Reference Values Manual. Brussels, Belgium, EORTC Publications, 2002